Lipid-based nanoparticle
| Part of a series of articles on |
| Nanomaterials |
|---|
| Carbon nanotubes |
|
| Fullerenes |
|
| Other nanoparticles |
|
| Nanostructured materials |
|
|
Lipid-based nanoparticles are very small spherical particles composed of lipids. They are a novel pharmaceutical drug delivery system (part of nanoparticle drug delivery), and a novel pharmaceutical formulation.[1][2] There are many subclasses of lipid-based nanoparticles such as: lipid nanoparticles (LNPs), solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs).
Sometimes the term "LNP" describes all lipid-based nanoparticles. In specific applications, LNPs describe a specific type of lipid-based nanoparticle, such as the LNPs used for the mRNA vaccine.[1][2][3]
Using LNPs for drug delivery was first approved in 2018 for the siRNA drug Onpattro.[4] LNPs became more widely known late in 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).[5]
- ^ a b Mehta, Meenu; Bui, Thuy Anh; Yang, Xinpu; Aksoy, Yagiz; Goldys, Ewa M.; Deng, Wei (2023-11-08). "Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development". ACS Materials Au. 3 (6): 600–619. doi:10.1021/acsmaterialsau.3c00032. PMC 10636777. PMID 38089666.
- ^ a b "Lipid-based nanoparticles: Manufacturing and inline size characterization". News-Medical. 2024-11-06. Retrieved 2024-12-01.
- ^ Cite error: The named reference
:02was invoked but never defined (see the help page). - ^ Cite error: The named reference
Stat4was invoked but never defined (see the help page). - ^ Pardi, Norbert; Hogan, Michael J.; Porter, Frederick W.; Weissman, Drew (April 2018). "mRNA vaccines — a new era in vaccinology". Nature Reviews Drug Discovery. 17 (4): 261–279. doi:10.1038/nrd.2017.243. PMC 5906799. PMID 29326426.